Sai Life Sciences unveils 2024–25 sustainability report

The company also reported significant progress toward its internally defined Sustainable Development Goals

Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr

Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025

Sai Life Sciences to double process R&D capacity with new facility in Hyderabad

The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization

Syngene International expands capabilities with new bioconjugation suite in Bengaluru

Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services

Aragen appoints Neeraj Garg as CEO - Discovery Solutions business

In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base

Syngene International invests in peptide laboratory in Bengaluru

Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services

Sai Life Sciences opens dedicated facility for veterinary APIs in Bidar

Sai Life Sciences completes Phase II of production block 11 at Bidar

With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL

Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr

The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase

Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US

NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline